Applied Therapeutics to Present Data on AT-001 for Treatment of Diabetic Cardiomyopathy at 56th Annual Meeting of the Europea...
17 Settembre 2020 - 1:00PM
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates against validated molecular targets in indications of
high unmet medical need, announced today that it will present
two poster presentations covering AT-001, a next generation aldose
reductase inhibitor (ARI), in Phase 3 development for Diabetic
Cardiomyopathy at the upcoming 56th Annual Meeting of the European
Association for the Study of Diabetes (EASD). The presentations
include data on the safety and specificity of AT-001, as well as
data on mechanistic protection from cellular damage during
hyperglycemia.
“We are pleased to present data at EASD
supporting development of AT-001 for diabetic complications,” said
Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied
Therapeutics. “We have previously presented data on the
improved potency and clinical safety profile of AT-001, which is
currently in a global registrational study for Diabetic
Cardiomyopathy. The data presented at EASD demonstrates the
improved target selectivity vs. “old” ARIs, underscoring AT-001’s
improved clinical safety profile, as well as compelling mechanistic
data demonstrating AT-001 protection from damage caused by
hyperglycemia.”
Presentation Details
Poster #629: AT-001 a new
aldose reductase inhibitor with improved selectivity and
specificity protects from cellular
damagePresenter: Riccardo Perfetti, M.D., Ph.D.,
Chief Medical Officer of Applied
TherapeuticsTime: Wednesday, September 23, 12:00 –
1:00 p.m. CEST (6:00 – 7:00 a.m. EDT)
Poster # 632: Addressing safety
and specificity with aldose reductase inhibition: development of
AT-001 for diabetic cardiomyopathyPresenter:
Riccardo Perfetti, M.D., Ph.D., Chief Medical Officer
of Applied TherapeuticsTime: Wednesday,
September 23, 12:00 – 1:00 p.m. CEST (6:00 – 7:00 a.m. EDT)
Slides will be available on the presentations and publications
section of the Applied Therapeutics website following the
conference.
About Applied TherapeuticsApplied
Therapeutics is a clinical-stage biopharmaceutical company
developing a pipeline of novel drug candidates against validated
molecular targets in indications of high unmet medical need. The
Company’s lead drug candidate, AT-007, is a novel central nervous
system penetrant aldose reductase inhibitor (ARI) for the treatment
of Galactosemia, a rare pediatric metabolic disease. The Company
initiated a pivotal Phase 1/2 clinical trial in June 2019,
read out positive top-line biomarker data in adult Galactosemia
patients in January 2020 and announced full data from the
trial in April 2020. A pediatric Galactosemia study commenced
in June 2020 and is currently ongoing. The Company is
also developing AT-001, a novel potent ARI that is being developed
for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal
fibrosis of the heart. The Company initiated a Phase 3
registrational study in DbCM in September 2019. The
preclinical pipeline also includes AT-003, an ARI designed to cross
through the back of the eye when dosed orally, for the treatment of
diabetic retinopathy, as well as novel dual PI3k inhibitors in
preclinical development for orphan oncology indications.
About AT-001 AT-001 is an investigational oral,
novel, potent Aldose Reductase inhibitor in Phase 3 clinical
development for the treatment of Diabetic Cardiomyopathy. AT-001
has been previously studied in a Phase 1/2 study in approximately
120 patients with type 2 diabetes, a subset of which had DbCM.
Investors: Maeve Conneighton (212) 600-1902 or
appliedtherapeutics@argotpartners.com
Media: Gleb Sagitov
media@appliedtherapeutics.com
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Lug 2023 a Lug 2024